Regeneron Pharmaceuticals Profile

Performance

1111
   

Odds of Distress

Fiscal Quarter End: December 31, 2019
Equity ratings for Regeneron Pharmaceuticals are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting August 23, 2019 and ending today November 21, 2019. Click here to learn more.

Regeneron Pharmaceuticals Profile

Next fiscal quarter end is expected on December 31, 2019. Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7674 people. more
NameRegeneron Pharmaceuticals
President CEO, DirectorLeonard SchleiferView All
Thematic Classifications
Active Investing Ideas
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Pharmaceuticals And Biosciences
InstrumentUSA Stock View All
RegionNorth America
Business Address777 Old Saw Mill River Road, Tarrytown, NY 10591-6707, United States
Foreign Associates
ExchangeBATS Exchange
CIK Number0000872589
ISINUS75886F1075
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.regeneron.com
Phone914 847 7000
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterSeptember 30, 2019
Last Fiscal Year EndDecember 31, 2018
Date Short InterestOctober 31, 2019
Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,674 people. The company currently falls under 'Large-Cap' category with current market capitalization of 38.51 B. Regeneron Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 107.98 M outstanding shares of which 2.12 M shares are at this time shorted by private and institutional investors with about 3.16 trading days to cover. REGENERON PHARMAC currently holds about 2.88 B in cash with 1.31 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 26.33.
Check Regeneron Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Regeneron Pharmaceuticals Target Price Odds Analysis

Odds Below 350.78HorizonTargetOdds Above 350.78
98.78%30 days 350.78 1.20%
Based on normal probability distribution, the odds of Regeneron Pharmaceuticals to move above current price in 30 days from now is about 1.2 (This Regeneron Pharmaceuticals probability density function shows the probability of Regeneron Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Regeneron Pharmaceuticals Top Holders

Regeneron Pharmaceuticals Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Capital World InvestorsCommon Shares8.2 M2.3 B
Blackrock IncCommon Shares6.3 M1.7 B
View Regeneron Pharmaceuticals Diagnostics

Regeneron Pharmaceuticals Income Statement Over Time

Direct Expenses    Earning Before Interest and Taxes EBIT    Net Income    

Regeneron Pharmaceuticals Key Fundamentals

Regeneron Pharmaceuticals Against Markets

Did you try this?

Run Content Syndication Now

   

Content Syndication

Quickly integrate customizable finance content to your own investment portal
All  Next Launch Module

Regeneron Pharmaceuticals Upcoming and Recent Events

Regeneron Pharmaceuticals Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportFebruary 5, 2020
Next Earnings ReportMay 5, 2020
Next Fiscal Quarter EndDecember 31, 2019
Next Fiscal Year EndFebruary 5, 2020
Last Quarter Report DateSeptember 30, 2019
Last Earning Anouncement DateDecember 31, 2018

Regeneron Pharmaceuticals Corporate Filings

Regeneron Pharmaceuticals SEC Reporting

Unclassified Corporate Event
Financial Statements and Exhibits. Unclassified Corporate Event. Results of Operations and Financial Condition
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Unclassified Corporate Event
Entry into a Material Definitive Agreement

Regeneron Pharmaceuticals Corporate Directors

Charles Baker Independent Director
Joseph Goldstein Independent Director
Anthony Coles Independent Director
Additionally take a look at Your Equity Center. Please also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Search macroaxis.com